Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CTX-112 by CRISPR Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
CTX-112 by CRISPR Therapeutics for B-Cell Chronic Lymphocytic Leukemia: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia. According to...
CTX-112 by CRISPR Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
CTX-112 by CRISPR Therapeutics for Follicular Lymphoma: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
CTX-112 by CRISPR Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
CTX-112 by CRISPR Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-112?
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell...